Generic Name and Formulations:
Posaconazole 40mg/mL; cherry flavor.

Company:
Merck & Co., Inc. 

Indications for NOXAFIL ORAL SUSPENSION:

Prophylaxis against invasive Aspergillus and Candida infections, in patients at high risk due to being severely immunocompromised, such as hematopoietic stem cell transplant recipients with Graft vs. Host Disease (GVHD) or those with hematologic malignancies with prolonged neutropenia due to chemotherapy. Treatment of oropharyngeal candidiasis, including refractory to itraconazole and/or fluconazole.

Adult Dose for NOXAFIL ORAL SUSPENSION:

Take within 20mins after a full meal; may take with liquid nutritional supplement or an acidic carbonated beverage (eg, gingerale) if cannot eat a full meal or del-rel tabs are not an option. ≥13yrs: Invasive fungal prophylaxis: 200mg 3 times daily, until recovery from neutropenia or immunosuppression. Oropharyngeal candidiasis: 100mg twice daily on Day 1, then 100mg once daily for 13 days; refractory: 400mg twice daily.

Children's Dose for NOXAFIL ORAL SUSPENSION:

<13yrs: not established.

See Also:

NOXAFIL

Pharmacological Class:

Triazole.

Contraindications:

Hypersensitivity to other azole antifungal agents. Concomitant sirolimus, ergot alkaloids, or HMG-CoA reductase inhibitors (eg, atorvastatin, lovastatin, simvastatin). Drugs that cause QT prolongation and are metabolized by CYP3A4 (eg, quinidine, pimozide).

Warnings/Precautions:

Tabs and oral susp are not interchangeable. Correct potassium, calcium, magnesium levels before starting. Proarrhythmic conditions. eva luate and monitor liver function tests before and during therapy; consider discontinuing if liver disease occurs. Patients who cannot eat a full meal or tolerate an oral nutritional supplement or those with severe renal impairment, severe diarrhea, or vomiting: monitor for breakthrough fungal infections. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions:

See Contraindications. Avoid drugs that lower posaconazole levels (eg, rifabutin, phenytoin, efavirenz, fosamprenavir); monitor for breakthrough fungal infections. Potentiates calcineurin-inhibitors (eg, cyclosporine, tacrolimus); monitor trough levels frequently during and at discontinuation of posaconazole; adjust tacrolimus and cyclosporine doses. Potentiates CYP3A4 substrates (eg, ritonavir, atazanavir, calcium channel blockers, vinca alkaloids, rifabutin, phenytoin), digoxin; monitor and consider dose reduction. Prolonged hypnotic and sedative effects with concomitant midazolam or other benzodiazepines (eg, alprazolam, triazolam). Monitor glucose levels with glipizide. Susp: avoid concomitant cimetidine, esomeprazole, metoclopramide; if needed, monitor for breakthrough fungal infections.

Adverse Reactions:

Fever, diarrhea, nausea, vomiting, headache, rigors, fatigue, anorexia, hypertension, abdominal pain, constipation, hypokalemia, cough, rash; lab abnormalities (eg, anemia, neutropenia, thrombocytopenia, bilirubinemia, increased liver enzymes), arrhythmias, QT prolongation.

Metabolism:

Hepatic (CYP3A4).

Elimination:

Fecal (major), renal.

Generic Availability:

NO

How Supplied:

Tabs—60; Susp—105mL (w. dosing spoon)